{"id":"allantoin","rwe":[{"pmid":"41900878","year":"2026","title":"Gelatin/Ascorbic Acid Scaffolds for Controlled Release of Allantoin: A Fully Natural Approach for Skin Tissue Regeneration Through Pro-Regenerative, Antimicrobial, and Keratinocyte-Supportive Properties.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"41869816","year":"2026","title":"Plasmidome, resistome, and virulence-associated gene characterization of Acinetobacter johnsonii in NASA cleanrooms and a clinical setting.","finding":"","journal":"Microbiology spectrum","studyType":"Clinical Study"},{"pmid":"41837579","year":"2026","title":"Self-Adaptive Allantoin@ZIF8 Nanocomposite Hydrogel with Resveratrol Synergy for MRSA-Infected Wound Regeneration.","finding":"","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","studyType":"Clinical Study"},{"pmid":"41829272","year":"2026","title":"Electrospun Chitosan-Poly(vinyl alcohol) Nanofibers Functionalized with Natural Bioactive Compounds: Design, Physicochemical Characterization and Release Profiles.","finding":"","journal":"Polymers","studyType":"Clinical Study"},{"pmid":"41802156","year":"2026","title":"Proton Concentration Tunes the Double-Layer Characteristics of Lead Catalysts to Boost the Electrosynthesis of Glyoxylic Acid.","finding":"","journal":"Nano letters","studyType":"Clinical Study"}],"_fda":{"id":"29a4e82a-2134-3542-e063-6394a90a96a5","set_id":"00edbc64-9d32-5751-e063-6294a90a400b","openfda":{"upc":["0850009221698"],"unii":["344S277G0Z"],"route":["TOPICAL"],"rxcui":["1442087"],"spl_id":["29a4e82a-2134-3542-e063-6394a90a96a5"],"brand_name":["DCH Scar"],"spl_set_id":["00edbc64-9d32-5751-e063-6294a90a400b"],"package_ndc":["72839-097-01"],"product_ndc":["72839-097"],"generic_name":["ALLANTOIN 0.5%"],"product_type":["HUMAN OTC DRUG"],"substance_name":["ALLANTOIN"],"manufacturer_name":["Derma Care Research Labs, LLC"],"application_number":["M016"],"is_original_packager":[true]},"purpose":["Skin Protectant."],"version":"2","warnings":["For external use only . When using this product keep out of eyes. Rinse with water to remove. Stop use and ask a doctor if the condition worsens or symptoms persist for more than 7 days or clear up and occur again within a few days. Do not use on deep or puncture wounds, animal bites, and serious burns."],"effective_time":"20241219","active_ingredient":["Allantoin 0.5%"],"inactive_ingredient":["Water, Alcohol Denat., PEG-4, Propylene Glycol, Xanthan Gum, Allium Cepa (Onion) Bulk Extract, Panthenol, Sodium Hyaluronate, Aloe Barbadensis Leaf Extract, Chamomilla Recutita (Matricaria) Flower Extract, Cucumis Sativus (Cucumber) Fruit Extract, Tocopherol, Glycerin, Juglans Nigra (Black Walnut) Leaf Extract, Ethylhexylglycerin, Benzyl Alcohol, Fragrance."],"indications_and_usage":["Apply as needed."],"dosage_and_administration":["Temporarily protects and helps relieve chapped or cracked skin."],"spl_product_data_elements":["DCH Scar Allantoin 0.5% POLYETHYLENE GLYCOL 200 TOCOPHEROL PANTHENOL WATER GLYCERIN ONION ALLANTOIN ALLANTOIN PROPYLENE GLYCOL XANTHAN GUM ALOE VERA LEAF BLACK WALNUT CHAMOMILE CUCUMBER ALCOHOL ETHYLHEXYLGLYCERIN BENZYL ALCOHOL HYALURONATE SODIUM"],"keep_out_of_reach_of_children":["Keep out of reach of children. If the product is swallowed, get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["Carton"]},"tags":[{"label":"allantoin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Topical","category":"route"},{"label":"Cutaneous","category":"route"},{"label":"Aerosol","category":"form"},{"label":"Cloth","category":"form"},{"label":"Concentrate","category":"form"},{"label":"Cream","category":"form"},{"label":"Active","category":"status"},{"label":"Itching of skin","category":"indication"},{"label":"Minor Skin Wound Pain","category":"indication"},{"label":"Pityriasis simplex","category":"indication"},{"label":"Psoriasis","category":"indication"},{"label":"Seborrheic dermatitis","category":"indication"},{"label":"Skin irritation","category":"indication"},{"label":"Dermatologic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"388 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"268 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"210 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"199 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"198 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"186 reports"},{"date":"","signal":"WEIGHT DECREASED","source":"FDA FAERS","actionTaken":"175 reports"},{"date":"","signal":"SOMNOLENCE","source":"FDA FAERS","actionTaken":"169 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"168 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"160 reports"}],"commonSideEffects":[],"contraindications":["Anemia due to enzyme deficiency","Deficiency of glucose-6-phosphate dehydrogenase","Disease of blood AND/OR blood-forming organ","Disease of liver","Folliculitis","Inflammatory dermatosis","Kidney disease","Open wound","Porphyria"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALLANTOIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:25:49.272737+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:26:05.379952+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:25:54.604588+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALLANTOIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:25:54.987728+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:25:48.019024+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:25:48.019076+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:25:56.482721+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL593429/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:25:55.698811+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"M016","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:25:48.019080+00:00"}},"allNames":"allantol","offLabel":[],"synonyms":["allantoin","5-Ureidohydantoin","allantion","allantol","glyoxyldiureid","glyoxyldiureide","glyoxylic diureide"],"timeline":[],"aiSummary":"Allantoin, marketed under the brand name Allantol, is a topical agent primarily indicated for the treatment of skin itching, currently holding a position in the over-the-counter skincare market. Its key strength lies in its mechanism of action, which promotes skin hydration and reduces inflammation by increasing the water content of the skin. The primary risk to Allantol's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generic formulations.","brandName":"Allantol","ecosystem":[{"indication":"Itching of skin","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""}],"globalPrevalence":null},{"indication":"Minor Skin Wound Pain","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"benzalkonium","slug":"benzalkonium","company":""},{"name":"benzethonium","slug":"benzethonium","company":""},{"name":"benzocaine","slug":"benzocaine","company":""}],"globalPrevalence":null},{"indication":"Pityriasis simplex","otherDrugs":[{"name":"ammonia","slug":"ammonia","company":""},{"name":"carbamide","slug":"carbamide","company":"Hospira"},{"name":"chloroxine","slug":"chloroxine","company":""},{"name":"ciclopirox","slug":"ciclopirox","company":"Medimetriks Pharms"}],"globalPrevalence":null},{"indication":"Psoriasis","otherDrugs":[{"name":"ammonia","slug":"ammonia","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""}],"globalPrevalence":125000000},{"indication":"Seborrheic dermatitis","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonia","slug":"ammonia","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"}],"globalPrevalence":null},{"indication":"Skin irritation","otherDrugs":[{"name":"aluminum acetate","slug":"aluminum-acetate","company":"Bayer Pharms"},{"name":"benzalkonium","slug":"benzalkonium","company":""},{"name":"benzethonium","slug":"benzethonium","company":""},{"name":"benzocaine","slug":"benzocaine","company":""}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"allantoin","explanation":"","oneSentence":"","technicalDetail":"Allantoin acts as a humectant, increasing the skin's water content by attracting and retaining moisture. This helps to maintain the skin's natural barrier function, reducing inflammation and promoting wound healing."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4268","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALLANTOIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALLANTOIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:37:51.768815","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:26:05.380063+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"allantoin","indications":{"approved":[{"name":"Itching of skin","source":"DrugCentral","snomedId":418363000,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Minor Skin Wound Pain","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Pityriasis simplex","source":"DrugCentral","snomedId":200767005,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Psoriasis","source":"DrugCentral","snomedId":9014002,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Seborrheic dermatitis","source":"DrugCentral","snomedId":50563003,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Skin irritation","source":"DrugCentral","snomedId":367466007,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07482787","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa","status":"NOT_YET_RECRUITING","sponsor":"Paradigm Therapeutics","startDate":"2026-05-15","conditions":["Epidermolysis Bullosa (EB)"],"enrollment":80,"completionDate":"2027-06-17"},{"nctId":"NCT07482813","phase":"PHASE3","title":"An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa","status":"NOT_YET_RECRUITING","sponsor":"Paradigm Therapeutics","startDate":"2026-07-15","conditions":["Epidermolysis Bullosa (EB)"],"enrollment":80,"completionDate":"2027-08-19"},{"nctId":"NCT05589402","phase":"PHASE1","title":"Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Rio Grande Valley","startDate":"2019-06-04","conditions":["Spinal Cord Injuries","Spine Disease","Stroke"],"enrollment":30,"completionDate":"2026-06-04"},{"nctId":"NCT06170346","phase":"PHASE2","title":"Effect of Topical Agents With Various Antioxidant Containts on Photodamage Skin Induced","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2022-11-01","conditions":["Photodamaged Skin"],"enrollment":11,"completionDate":"2024-01-31"},{"nctId":"NCT05958251","phase":"","title":"The Use of Arnica Montana in the Cicatrization of the Umbilical Cord","status":"COMPLETED","sponsor":"Ospedale Buon Consiglio Fatebenefratelli","startDate":"2022-05-30","conditions":["Umbilical Cord Issue"],"enrollment":326,"completionDate":"2022-11-02"},{"nctId":"NCT06178367","phase":"PHASE3","title":"Effectiveness and Safety of Topical Hyaluronic Acid of Different Molecular Weights in Xerotic Skin Treatment","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2023-08-26","conditions":["Xerosis Cutis"],"enrollment":36,"completionDate":"2023-09-30"},{"nctId":"NCT06338410","phase":"NA","title":"Effect of Kangaroo Mother Care on Oxidative Stress and Bonding","status":"COMPLETED","sponsor":"University of Health Sciences Lahore","startDate":"2023-08-01","conditions":["Kangaroo Mother Care","Oxidative Stress"],"enrollment":40,"completionDate":"2024-03-20"},{"nctId":"NCT05983302","phase":"PHASE2,PHASE3","title":"Elimination of Odor and Treatment of Malodorous Recalcitrant Wounds by Using Supraz and PRP-FG Versus Standard of Care","status":"RECRUITING","sponsor":"Mashhad University of Medical Sciences","startDate":"2023-08-20","conditions":["Wounds and Injuries"],"enrollment":40,"completionDate":"2024-03-20"},{"nctId":"NCT06122467","phase":"NA","title":"A Single Group Study to Evaluate the Efficacy of a Cosmetic Product Line on Acne Symptoms","status":"COMPLETED","sponsor":"Menning Labs","startDate":"2023-10-02","conditions":["Acne"],"enrollment":36,"completionDate":"2023-12-31"},{"nctId":"NCT05284487","phase":"NA","title":"Clinical Trial to Evaluate Safety and Efficacy of Jalosome® Soothing Gel.","status":"UNKNOWN","sponsor":"Welcare Industries SpA","startDate":"2023-03-27","conditions":["Radiation-induced Dermatitis"],"enrollment":57,"completionDate":"2024-03"},{"nctId":"NCT05796635","phase":"NA","title":"An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold Sores","status":"COMPLETED","sponsor":"Focus Consumer Healthcare","startDate":"2023-01-04","conditions":["Cold Sores"],"enrollment":80,"completionDate":"2023-02-20"},{"nctId":"NCT03401749","phase":"PHASE4","title":"Preadmission Skin Wipe Use for Surgical Site Infection Prophylaxis in Adult Orthopaedic Surgery Patients","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2018-11-01","conditions":["Surgical Site Infection"],"enrollment":203,"completionDate":"2020-12-01"},{"nctId":"NCT05105139","phase":"","title":"Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2021-11-29","conditions":["Seborrheic Dermatitis","Psoriasis of Scalp"],"enrollment":90,"completionDate":"2022-02-25"},{"nctId":"NCT04325490","phase":"PHASE4","title":"Tapioca Starch Stimutex AS, Aloe Barbadensis, Rose Hip Oil, Allantoin Comparing With Topical 1% Hydrocortisone Cream","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2019-10-01","conditions":["Intertrigo"],"enrollment":40,"completionDate":"2020-09-30"},{"nctId":"NCT02384460","phase":"PHASE3","title":"ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa","status":"COMPLETED","sponsor":"Scioderm, Inc.","startDate":"2015-03-11","conditions":["Epidermolysis Bullosa"],"enrollment":169,"completionDate":"2017-07-05"},{"nctId":"NCT02014376","phase":"PHASE2","title":"Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa","status":"COMPLETED","sponsor":"Scioderm, Inc.","startDate":"2014-01-06","conditions":["Epidermolysis Bullosa"],"enrollment":48,"completionDate":"2014-06-24"},{"nctId":"NCT02090283","phase":"PHASE2","title":"Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa","status":"TERMINATED","sponsor":"Scioderm, Inc.","startDate":"2014-03-26","conditions":["Epidermolysis Bullosa"],"enrollment":42,"completionDate":"2018-09-14"},{"nctId":"NCT02670330","phase":"PHASE3","title":"Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa","status":"TERMINATED","sponsor":"Scioderm, Inc.","startDate":"2015-06-09","conditions":["Epidermolysis Bullosa"],"enrollment":152,"completionDate":"2018-09-03"},{"nctId":"NCT04046783","phase":"","title":"Patch With Onion Extract and Allantoin for C-section Scar","status":"COMPLETED","sponsor":"University of Salerno","startDate":"2019-03-02","conditions":["Cesarean Section; Dehiscence","Scar Keloid","Wound Heal"],"enrollment":93,"completionDate":"2019-07-31"},{"nctId":"NCT02413099","phase":"PHASE4","title":"The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction","status":"COMPLETED","sponsor":"Hyun Jun Park","startDate":"2012-02","conditions":["Erectile Dysfunction"],"enrollment":44,"completionDate":"2013-01-03"},{"nctId":"NCT03611283","phase":"NA","title":"Topical Management of Xerostomia With Dry Mouth Products","status":"COMPLETED","sponsor":"Rosa María López-Pintor Muñoz","startDate":"2016-10-03","conditions":["Xerostomia","Sjogren's Syndrome"],"enrollment":28,"completionDate":"2017-11-30"},{"nctId":"NCT03578900","phase":"PHASE4","title":"Quality of Life and Sjögren Syndrome","status":"COMPLETED","sponsor":"Grupo de Investigação em Bioquímica e Biologia Oral","startDate":"2013-01-01","conditions":["Xerostomia","Hyposalivation","Quality of Life","Sjogren's Syndrome"],"enrollment":289,"completionDate":"2016-12-31"},{"nctId":"NCT00825565","phase":"PHASE2","title":"Study of Alwextin® Cream in Treating Epidermolysis Bullosa","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2009-02","conditions":["Epidermolysis Bullosa"],"enrollment":8,"completionDate":"2010-11"},{"nctId":"NCT02708628","phase":"NA","title":"The Efficacy of Extract of Allium Cepae, Allantoin and Heparin in Patients With Proven Scar Development","status":"COMPLETED","sponsor":"Suleymaniye Birth And Women's Health Education And Research Hospital","startDate":"2015-12","conditions":["Cicatrix"],"enrollment":120,"completionDate":"2016-10"},{"nctId":"NCT01910896","phase":"NA","title":"Effectiveness and Safety Study of Overnight Intensive Patch in Scars","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2013-10","conditions":["Post Dermatological Surgery Scars"],"enrollment":125,"completionDate":"2015-07"},{"nctId":"NCT01112371","phase":"PHASE4","title":"Contractubex Treatment in Scars After Abdominal Caesarean Section","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2011-02","conditions":["Scars"],"enrollment":61,"completionDate":"2012-02"},{"nctId":"NCT01863407","phase":"PHASE3","title":"Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)","status":"UNKNOWN","sponsor":"Beijing Bozhiyin T&S Co., Ltd.","startDate":"2013-04","conditions":["Postoperative Ileus"],"enrollment":480,"completionDate":"2014-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Aerosol, Cloth, Concentrate, Cream","formulations":[{"form":"AEROSOL, FOAM","route":"TOPICAL","productName":"PLAGENTRA BABY BUBBLE WASH"},{"form":"AEROSOL, SPRAY","route":"TOPICAL","productName":"Allantoin"},{"form":"CLOTH","route":"TOPICAL","productName":"QYO QYO Tangerine Bright Moist Mask Pack"},{"form":"CONCENTRATE","route":"TOPICAL","productName":"Anubis Barcelona"},{"form":"CONCENTRATE","route":"TOPICAL","productName":"Anubis Barcelona Regul OIl"},{"form":"CREAM","route":"CUTANEOUS","productName":"BIOWHITE BEAUTY SERUM"},{"form":"CREAM","route":"TOPICAL","productName":"Scar Gel Advanced Formula"},{"form":"CREAM","route":"TOPICAL","productName":"Scar Reducer Intensive Herbal and Nutrient"},{"form":"CREAM","route":"TOPICAL","productName":"ANUBISMED"},{"form":"CREAM","route":"TOPICAL","productName":"ATOBOS"},{"form":"CREAM","route":"TOPICAL","productName":"ATOBOS CENTELLA BABY"},{"form":"CREAM","route":"TOPICAL","productName":"AVANCE CURE BARRIER"},{"form":"CREAM","route":"TOPICAL","productName":"AVANCE CURE INCONTINENCE"},{"form":"CREAM","route":"TOPICAL","productName":"Anubis Barcelona Regul Oil"},{"form":"CREAM","route":"TOPICAL","productName":"AnubisMed"}]},"crossReferences":{"NUI":"N0000146926","MMSL":"4149","NDDF":"002009","UNII":"344S277G0Z","VUID":"4018613","CHEBI":"CHEBI:15676","VANDF":"4018613","RXNORM":"508","UMLSCUI":"C0002083","chemblId":"CHEMBL593429","ChEMBL_ID":"CHEMBL593429","KEGG_DRUG":"D00121","DRUGBANK_ID":"DB11100","PDB_CHEM_ID":" 2AL","PUBCHEM_CID":"204","SNOMEDCT_US":"395933009","MESH_DESCRIPTOR_UI":"D000481"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1767,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 22","pmid":"41900878","title":"Gelatin/Ascorbic Acid Scaffolds for Controlled Release of Allantoin: A Fully Natural Approach for Skin Tissue Regeneration Through Pro-Regenerative, Antimicrobial, and Keratinocyte-Supportive Properties.","journal":"Pharmaceutics"},{"date":"2026 Mar 23","pmid":"41869816","title":"Plasmidome, resistome, and virulence-associated gene characterization of Acinetobacter johnsonii in NASA cleanrooms and a clinical setting.","journal":"Microbiology spectrum"},{"date":"2026 Mar 16","pmid":"41837579","title":"Self-Adaptive Allantoin@ZIF8 Nanocomposite Hydrogel with Resveratrol Synergy for MRSA-Infected Wound Regeneration.","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"},{"date":"2026 Feb 27","pmid":"41829272","title":"Electrospun Chitosan-Poly(vinyl alcohol) Nanofibers Functionalized with Natural Bioactive Compounds: Design, Physicochemical Characterization and Release Profiles.","journal":"Polymers"},{"date":"2026 Mar 25","pmid":"41802156","title":"Proton Concentration Tunes the Double-Layer Characteristics of Lead Catalysts to Boost the Electrosynthesis of Glyoxylic Acid.","journal":"Nano letters"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:26:05.380063+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}